| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | VACWR062 |
| Uniprot No | P21607 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 180-429aa |
| 氨基酸序列 | IWAYLSKKDTGIEFADNDRQDIYTLFQQTGRIVHSNLTETFRDYIFPGDKTSYWVWLNESIANDADIVLNRHAITMYDKILSYIYSEIKQGRVNKNMLKLVYIFEPEKDIRELLLEIIYDIPGDILSIIDAKNDDWKKYFISFYKANFINGNTFISDRTFNEDLFRVVVQIDPEYFDNERIMSLFSTSAADIKRFDELDINNSYISNIIYEVNDITLDTMDDMKKCQIFNEDTSYYVKEYNTYLFLHESD |
| 预测分子量 | 42.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VACWR062重组蛋白的模拟参考文献示例(注：实际文献需通过学术数据库验证，以下内容为假设性概括)：
---
1. **文献名称**: *"VACWR062: A Novel Immune Modulatory Protein in Vaccinia Virus"*
**作者**: Smith J, et al.
**摘要**: 研究通过重组表达技术揭示了VACWR062蛋白在痘苗病毒免疫逃逸中的作用，证明其可抑制宿主NF-κB信号通路，降低促炎因子表达。
2. **文献名称**: *"High-Yield Expression and Crystallographic Analysis of Recombinant VACWR062"*
**作者**: Lee H, et al.
**摘要**: 报道了在大肠杆菌系统中优化VACWR062重组蛋白表达与纯化的方法，并通过晶体结构解析发现其与宿主靶点结合的潜在位点。
3. **文献名称**: *"Functional Characterization of VACWR062 in Viral Replication via Recombinant Knockout Strains"*
**作者**: Zhang R, et al.
**摘要**: 利用重组基因敲除病毒株证实VACWR062对痘苗病毒复制至关重要，体外补充重组蛋白可部分恢复病毒在宿主细胞中的增殖能力。
4. **文献名称**: *"VACWR062 Interaction with Host Kinases and Implications for Antiviral Therapy"*
**作者**: Brown K, et al.
**摘要**: 发现重组VACWR062蛋白通过结合宿主JAK激酶干扰干扰素信号，为开发靶向该蛋白的抗病毒策略提供了依据。
---
**提示**：实际研究中VACWR062可能需结合痘苗病毒基因组数据库(如NCBI Gene ID)确认准确性。建议使用关键词“VACWR062 recombinant protein”或“Vaccinia virus WR062”在PubMed、Web of Science等平台检索最新文献。
VACWR062 is a recombinant protein derived from the vaccinia virus (VACV), a member of the *Poxviridae* family. Vaccinia virus has historically been pivotal in vaccine development, most notably as the live-virus vaccine used to eradicate smallpox. The VACWR062 gene, encoded by the Western Reserve (WR) strain of VACV, is a conserved viral protein whose precise biological role remains under investigation. Studies suggest it may contribute to viral replication, immune evasion, or host-pathogen interactions, though its exact mechanism is less characterized compared to other VACV proteins like A27 or B5. which are known to mediate viral entry or egress.
Recombinant VACWR062 is typically expressed in heterologous systems (e.g., *E. coli* or mammalian cells) for structural and functional studies. Its production enables researchers to explore its potential as a diagnostic antigen, a vaccine component, or a therapeutic target. Interest in VACWR062 also stems from its possible role in modulating host immune responses, such as interfering with innate immune signaling pathways (e.g., Toll-like receptors) or altering cytokine production. Additionally, recombinant VACWR062 may serve as a tool to study poxvirus biology, particularly in understanding how VACV proteins interact with host cells to establish infection or evade detection.
Recent research has focused on characterizing its immunogenicity, aiming to assess its utility in next-generation vaccines or immunotherapies. For instance, recombinant VACWR062 could be evaluated as part of a subunit vaccine against poxviruses or engineered into viral vectors for cancer immunotherapy. Its structural analysis (e.g., crystallography or cryo-EM) may further reveal conserved epitopes for cross-reactive antibodies. Overall, VACWR062 represents a niche yet intriguing target in virology, bridging fundamental research and translational applications in infectious diseases and immunology.
×
